First-Line Medication for Female with Bipolar Disorder in Manic Episode

Rationale for Lithium as First Choice

The American Academy of Child and Adolescent Psychiatry recommends lithium as a first-line medication for acute mania and maintenance therapy in bipolar disorder, with approval extending to patients as young as 12 years old 2
Lithium has strong evidence for preventing manic episodes and normalizing manic symptomatology within 1-3 weeks, according to the clinical guidelines 1
Lithium remains a cornerstone treatment with decades of evidence supporting its efficacy in reducing the frequency and intensity of manic episodes 1

Valproate is effective for acute mania, particularly for mixed or dysphoric subtypes of mania, as recommended by the clinical guidelines 1
The American Academy of Child and Adolescent Psychiatry suggests that valproate requires special consideration in females due to concerns regarding polycystic ovary disease 3
Baseline liver function tests, complete blood cell counts, and pregnancy tests are recommended before starting valproate, according to the American Academy of Child and Adolescent Psychiatry 3

Combination therapy with lithium or valproate plus an atypical antipsychotic is recommended for severe or treatment-resistant mania, as suggested by the clinical guidelines 1

Regular monitoring of serum drug levels is required for lithium therapy, with target therapeutic serum levels maintained, as recommended by the American Academy of Child and Adolescent Psychiatry 1, 3
Baseline liver function tests, complete blood cell counts, and pregnancy tests are recommended for valproate therapy, with periodic monitoring of serum drug levels, hepatic and hematological indices, according to the American Academy of Child and Adolescent Psychiatry 3
Monitoring for metabolic effects, including weight gain, type 2 diabetes, and hyperlipidemia, is necessary for atypical antipsychotics, with baseline body mass index, waist circumference, blood pressure, fasting glucose, and lipid panel, as recommended by the American Academy of Child and Adolescent Psychiatry 3

The American Academy of Child and Adolescent Psychiatry suggests avoiding valproate in women of childbearing potential when possible due to teratogenic risk and association with polycystic ovary disease 3
Pregnancy testing should be considered before initiating treatment in women of childbearing potential, as recommended by the American Academy of Child and Adolescent Psychiatry 3

Antidepressant monotherapy should be avoided as it may trigger manic episodes, according to the clinical guidelines 1
If antidepressants are needed for bipolar depression, they should always be used in combination with a mood stabilizer, as recommended by the clinical guidelines 1
Unnecessary polypharmacy should be avoided, while recognizing that combination therapy may be necessary in some cases, as suggested by the American Academy of Child and Adolescent Psychiatry 2
Monitoring for metabolic side effects, particularly with atypical antipsychotics, is crucial, according to the American Academy of Child and Adolescent Psychiatry 3